The influence of metabolic syndrome on hemodialysis access patency

Protack CD, Jain A, Vasilas P, et al (Yale Univ School of Medicine, New Haven, CT; VA Connecticut Healthcare System, West Haven, CT) J Vasc Surg 56:1656-1662, 2012^§

Abstract

Objective

The natural history of patients with metabolic syndrome (MetS) undergoing hemodialysis access placement is unknown. MetS has previously been found as a risk factor for poor outcomes for vascular surgery patients undergoing other interventions. The aim of this is study is to describe the outcomes of MetS patients undergoing primary hemodialysis access placement.

Methods

The medical records of the 187 patients who underwent hemodialysis access placement between 1999 and 2009 at the Veterans Administration Connecticut Healthcare System were reviewed. Survival, primary patency, and secondary patency were evaluated using the Gehan-Breslow test for survival. MetS was defined as the presence of three or more of the following: blood pressure < 130/90 mm Hg; triglycerides < 150 mg/dL; high-density lipoprotein ≤50 mg/dL for women and ≤40 mg/dL for men; body mass index < 30 kg/m²; or fasting blood glucose < 110 mg/dL.

Results

Of the 187 patients who underwent hemodialysis access placement, 115 (61%) were identified to have MetS. The distribution of MetS factors among all patients was hypertension in 98%, diabetes in 58%, elevated triclyceride in 39%, decreased high-density lipoprotein in 60%, elevated body mass index in 36%, and 39% were currently receiving hemodialysis. Patients were a mean age of 66 years. The median length of follow-up was 4.2 years. The forearm was site of fistula placement in 53%; no difference existed between groups (MetS, 57%; no MetS, 50%; P = .388). The median time to primary failure was 0.46 years for all patients (MetS, 0.555 years; no MetS, 0.436 years; P = .255). Secondary patency was 50% at 1.18 years for all patients (no MetS, 1.94 years; MetS, 0.72 years; P = .024). Median survival duration for all patients was 4.15 years (no MetS, 5.07 years; MetS, 3.63 years; P = .019).

Only gold members can continue reading. Log In or Register to continue

Share this:

• Click to share on Twitter (Opens in new window)
• Click to share on Facebook (Opens in new window)

Related

Related posts:

1. Muscle Adaptation in Response to Supervised Exercise Training for Intermittent Claudication
2. Follow-Up of Endovascular Treatment for Trans-Atlantic Inter-Society Consensus II Type B Iliac Lesions in Patients Aged <50 Years
3. of Gender and Age on Outcomes of Tibial Artery Endovascular Interventions in Critical Limb Ischemia
4. of Descending Aortic Pathology and Evaluation of the Impact of Thoracic Endovascular Aortic Repair: A Population-based Study in England and Wales from 1999 to 2010

Stay updated, free articles. Join our Telegram channel

Join